Impact of metabolic syndrome on re-stenosis development: role of drug-eluting stents.
Metabolic syndrome (MetS) is defined as a cluster of numerous cardiovascular risk factors, which encompasses obesity, dyslipidaemia, insulin resistance and hypertension. Patients with MetS are more prone to developing cardiovascular events than other patients. To date, several approaches such as physical exercise, dietary control and invasive and non-invasive therapeutic interventions for dyslipidaemia, hypertension and insulin resistance have been used to manage MetS. However, there is a progressive elevation in the incidence of fatal and non-fatal cardiovascular events due to the increased prevalence of obesity and diabetes. Percutaneous coronary intervention has emerged over the last few years as an effective revascularisation strategy for those with coronary artery disease, in parallel with the development of effective anti-platelet medications and newer drug-eluting stents. In recent years, considerable research efforts have been undertaken to elucidate the pathophysiology of re-stenosis and develop strategies to prevent re-stenosis following percutaneous transluminal coronary angioplasty and stent implantation. Although the rate of stent re-stenosis and target-lesion revascularisation has been reduced, there is little information in the literature on the outcome of MetS in the pathophysiology of re-stenosis. In this review article, we summarise the recent development and progress on re-stenosis and the role of drug-eluting stents, particularly in MetS.
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
S N
SN
Goyal
S
S
Bharti
B
B
Krishnamurthy
Y
Y
Agrawal
S K
SK
Ojha
D S
DS
Arya
D015906:Angioplasty, Balloon, Coronary; D003324:Coronary Artery Disease / Q000209:etiology / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007249:Inflammation / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000150:complications*; D012307:Risk Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents